BIOVECTRA is honored with 2025 CDMO Leadership Award for biologics

BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics.

Research sheds light on the psychology behind patience and impatience

Patience -; like its corollary impatience -; has always been a sort of “I know it when I see it” concept. And that didn’t sit

December 20, 2024

ENHERTU gains conditional approval in China

ENHERTU is indicated for patients with unresectable or metastatic NSCLC with activating HER2 mutations who have previously undergone systemic therapy. Credit: Nemes Laszlo/Shutterstock. Daiichi Sankyo

October 14, 2024

Small studies offer hope CAR-T can fight an aggressive brain cancer

A series of new studies are raising hopes that CAR-T, a process in which treatments are made by genetically editing a patient’s own white blood

March 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.